Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29:55:e07382021.
doi: 10.1590/0037-8682-0738-2021. eCollection 2022.

Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study

Jose Diego Brito-Sousa  1   2 , Jeffe Phanor  1   2 , Patricia Carvalho da Silva Balieiro  1   2 , Alexandre Vilhena Silva-Neto  1   2 , Jady Shayenne Mota Cordeiro  1   2 , Sheila Vitor-Silva  1   3 , Maxwell Mendes  1 , Vanderson Souza Sampaio  1   2   4 , Gisely Cardoso de Melo  1   2 , Marcus Lacerda  1   2   5 , Wuelton Monteiro  1   2
Affiliations

Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study

Jose Diego Brito-Sousa et al. Rev Soc Bras Med Trop. .

Abstract

Background: Although primaquine (PQ) is indicated for G6PD-deficient patients, data on weekly PQ use in Brazil are limited.

Methods: We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020.

Results: Patients receiving weekly PQ treatment had a lower risk of recurrence than those receiving daily PQ treatment (risk ratio: 0.62, 95% confidence interval: 0.41-0.94), using a model adjusted for study site.

Conclusions: Weekly PQ use did not increase the risk of malaria recurrence. Further studies with larger populations are warranted.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no conflict of interest.

Figures

FIGURE 1:
FIGURE 1:. Time to first recurrence between groups using weekly and daily PQ regimens within 180 days. Cox-proportional hazard model was used adjusted by study site. HR: hazard ratio; CI: confidence interval.
See this image and copyright information in PMC

References

    1. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418–418. - PMC - PubMed
    1. Brito-Sousa JD, Santos TC, Avalos S, Fontecha G, Melo GC, Val F, et al. Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon. Clin Infect Dis. 2019;69(8):1440–1442. doi: 10.1093/cid/ciz122. - DOI - PubMed
    1. Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM, et al. Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes. Malar J. 2014;13:70–70. doi: 10.1186/1475-2875-13-70. - DOI - PMC - PubMed
    1. World Health Organization . Testing for G6PD deficiency for safe use of primaquine in radical cure of Plasmodim vivax and P. ovale malaria. WHO Policy Br; 2016. http://apps.who.int/iris/bitstream/10665/250297/1/WHO-HTM-GMP-2016.9-eng...
    1. Alving A, Johnson C, Tarlov A, Brewer G, Kellermeyer R, Carson P. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22(6):621–631. - PMC - PubMed